Newsroom | 49764 results

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology reported the grant of inducement awards to two new hires in January 2026, as required under Nasdaq Listing Rule 5635(c)(4)....

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced it will report business updates and financial results for the fourth quarter and full year 2025 after market close on Thursday, February 19, 2026. Company management will host a corresponding conference call beginning at 1:30pm PT / 4:30pm ET. Investors interested in...

LEIDEN, The Netherlands--(BUSINESS WIRE)--Leyden Laboratories B.V. (the “Company” or “Leyden Labs”) today announced landmark preclinical and clinical data in Science Translational Medicine supporting the development of their antibody-based nasal sprays to prevent influenza infection by neutralizing virus at portal of entry. The data directly underpin the Company’s PanFlu program, which aims to provide broad, immediate protection against influenza through intranasal antibody delivery. In two cli...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Results from a recently published randomized, double-blind, placebo-controlled clinical trial show that supplementation with Brightseed® BioMetaControl, containing the naturally occurring bioactive compounds N-trans caffeoyltyramine (NCT) and N-trans feruloyltyramine (NFT), significantly improved markers of glycemic control in adults with prediabetes. The study was published in the peer-reviewed journal Bioactive Compounds in Health and Disease. In...

PARK CITY, Utah & IRVINE, Calif.--(BUSINESS WIRE)--BioSelective Capital Investments and Shayan Enterprises, LLC, a Utah-based risk-capital investment firm, today announced the successful acquisition of BioDuro’s drug product development and manufacturing operations in Irvine, California, resulting in the formation of Forma Life Sciences, Inc. (FORMA), a Delaware corporation established to hold and operate the acquired assets. The transaction includes two highly accredited facilities supporting...

HOUSTON--(BUSINESS WIRE)--InGeneron, Inc., a biotechnology company pioneering autologous regenerative cell therapies, today announced receipt of a CE Certificate (No. 28620235524 issued January 19, 2026) for the Transpose Ultra® (Sterile Kit) and the Processing Unit (Centrifuge) in accordance with Regulation (EU) 2017/745 on medical devices (the Medical Device Regulation, MDR). Intertek Medical Notified Body AB (2862) conducted an extensive review of the submitted Technical Documentation and pe...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company focused on delivering a new class of innovative immunotherapies for patients with cancer and other incurable diseases, announced today that a late-breaking abstract for its novel D-Domain binder in anitocabtagene autoleucel (anito-cel) has been accepted for presentation at the 2026 Tandem Meetings. BCMA-directed CAR T therapies are effective in treating relapsed and/or refractory multiple myeloma, with...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that Medsafe, the New Zealand Medicines and Medical Devices Safety Authority, has granted approval for its clinical trial application (CTA) for Study SRP-1005-101, also known as INSIGHTT. Sarepta expects to initiate this first-in-human clinical trial of SRP-1005 (formerly ARO-HTT) in the second quarter of 2026. SRP-1005 is an investigational sm...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will host a conference call and webcast on Thursday, February 12, 2026, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2026 third quarter ended December 31, 2025, and pro...

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene”), a clinical-stage, non-viral genetic medicines company, today announced that Ron Cooper, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026, at 2:30 p.m. ET. A live webcast of the fireside chat can be accessed on the "Events and Presentations” page under the “Investors” section of the enGene website at...